Bristol Myers Squibb Company $BMY Shares Bought by Kestra Advisory Services LLC

Kestra Advisory Services LLC lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 21.9% during the first quarter, HoldingsChannel.com reports. The firm owned 239,312 shares of the biopharmaceutical company’s stock after purchasing an additional 42,995 shares during the period. Kestra Advisory Services LLC’s holdings in Bristol Myers Squibb were worth $14,514,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in BMY. Vanguard Group Inc. boosted its holdings in Bristol Myers Squibb by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after buying an additional 2,743,759 shares in the last quarter. State Street Corp lifted its position in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock valued at $5,285,065,000 after acquiring an additional 1,385,206 shares during the period. Geode Capital Management LLC lifted its position in shares of Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after acquiring an additional 6,084,046 shares during the period. Norges Bank purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $1,947,272,000. Finally, AQR Capital Management LLC grew its holdings in shares of Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after acquiring an additional 16,332,924 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on BMY shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 2nd. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Cantor Fitzgerald restated a “neutral” rating and issued a $54.00 price target on shares of Bristol Myers Squibb in a research report on Monday, July 6th. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Finally, HSBC boosted their price objective on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $61.25.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock traded down $0.41 during trading on Friday, hitting $57.53. 11,202,444 shares of the company were exchanged, compared to its average volume of 12,071,738. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The stock has a market capitalization of $117.49 billion, a price-to-earnings ratio of 16.16, a P/E/G ratio of 0.16 and a beta of 0.23. The firm has a 50 day moving average price of $56.83 and a 200 day moving average price of $57.62.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts expect that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bank of America lowered its price target slightly to $66 from $67 but kept a Buy rating, signaling continued upside potential for Bristol Myers Squibb. Benzinga
• Positive Sentiment: Bristol Myers Squibb’s addition to defensive and value-defensive Russell indices could broaden demand from index-tracking and conservative institutional investors. Yahoo Finance
• Positive Sentiment: The company’s QUILS lung cancer detection program is expanding into new states, reinforcing its reputation in oncology and public-health initiatives. Yahoo Finance

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.